Literature DB >> 10419856

Phosphodiesterase 4 inhibitors as novel anti-inflammatory agents.

A M Doherty1.   

Abstract

Preclinical and clinical studies of phosphodiesterase 4 inhibitors have shown that these agents may find utility in a wide range of inflammatory disorders, including asthma, chronic obstructive pulmonary disease, atopic dermatitis, rheumatoid arthritis, multiple sclerosis and various neurological disorders. The future of this class of drugs will depend upon the ability to demonstrate a reasonable safety margin against emesis and other typical phosphodieserase (PDE4) side effects, as well as in identification of the inflammatory disorder(s) most relevant to PDE4 inhibition.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10419856     DOI： 10.1016/S1367-5931(99)80068-4

Source DB:  PubMed          Journal:  Curr Opin Chem Biol        ISSN： 1367-5931            Impact factor:   8.822


  11 in total

1.  The biphasic immunoregulation of pyrimidylpiperazine (Y-40138) is IL-10 sensitive and requires NF-kappa B targeting in the alveolar epithelium.

Authors:  J J Haddad; B Safieh-Garabedian; N E Saadé; S C Land
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

2.  Redox/ROS regulation of lipopolysaccharide-induced mitogen-activated protein kinase (MAPK) activation and MAPK-mediated TNF-alpha biosynthesis.

Authors:  J J Haddad; S C Land
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

3.  Genome-Wide Association Analysis of Single-Breath DlCO.

Authors:  Phuwanat Sakornsakolpat; Meredith McCormack; Per Bakke; Amund Gulsvik; Barry J Make; James D Crapo; Michael H Cho; Edwin K Silverman
Journal:  Am J Respir Cell Mol Biol       Date:  2019-05       Impact factor: 6.914

4.  Dextran sulfate sodium-induced colonic histopathology, but not altered epithelial ion transport, is reduced by inhibition of phosphodiesterase activity.

Authors:  N Diaz-Granados; K Howe; J Lu; D M McKay
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

5.  Rolipram inhibits leukocyte-endothelial cell interactions in vivo through P- and E-selectin downregulation.

Authors:  María-Jesús Sanz; Angeles Alvarez; Laura Piqueras; Miguel Cerdá; Andrew C Issekutz; Roy R Lobb; Julio Cortijo; Esteban J Morcillo
Journal:  Br J Pharmacol       Date:  2002-04       Impact factor: 8.739

Review 6.  PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization.

Authors:  Miles D Houslay; David R Adams
Journal:  Biochem J       Date:  2003-02-15       Impact factor: 3.857

7.  PDE4 inhibition suppresses IL-17-associated immunity in dry eye disease.

Authors:  Zahra Sadrai; William Stevenson; Andre Okanobo; Yihe Chen; Thomas H Dohlman; Jing Hua; Francisco Amparo; Sunil K Chauhan; Reza Dana
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-06-14       Impact factor: 4.799

8.  Mitigation of stress-induced gastric mucosal lesions by a specific type IV phosphodiesterase inhibitor.

Authors:  Sayuri Kato; Michiro Otaka; Masaru Odashima; Toshihiro Sato; Mario Jin; Tamotsu Matsuhashi; Noriaki Konishi; Sumio Watanabe
Journal:  Dig Dis Sci       Date:  2007-03       Impact factor: 3.487

9.  Expression, intracellular distribution and basis for lack of catalytic activity of the PDE4A7 isoform encoded by the human PDE4A cAMP-specific phosphodiesterase gene.

Authors:  Lee Ann Johnston; Suat Erdogan; York Fong Cheung; Michael Sullivan; Rachael Barber; Martin J Lynch; George S Baillie; Gino Van Heeke; David R Adams; Elaine Huston; Miles D Houslay
Journal:  Biochem J       Date:  2004-06-01       Impact factor: 3.857

Review 10.  Update on the Pathogenesis and Therapy of Atopic Dermatitis.

Authors:  Huaguo Li; Zhen Zhang; Hui Zhang; Yifeng Guo; Zhirong Yao
Journal:  Clin Rev Allergy Immunol       Date:  2021-08-02       Impact factor: 8.667
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.